Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress

Pharmaceutical Investing

Cellular Biomedicine (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported financial results and business highlights for the first quarter ended March 31, 2018. As quoted in the press release: “Early in 2018, we’ve made notable progress with our immuno-oncology platform as the …

Cellular Biomedicine (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported financial results and business highlights for the first quarter ended March 31, 2018.

As quoted in the press release:

“Early in 2018, we’ve made notable progress with our immuno-oncology platform as the China Food and Drug Administration (CFDA) accepted the Company’s Investigational New Drug Applications (IND) for “C-CAR011” anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with B-cell Non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic leukemia (ALL),” commented Tony Liu, Chief Executive Officer of CBMG. “We are advancing recognized CAR-T therapies through China’s regulatory pathway, with our state of the art GMP facility, which houses a CBMG-GE Healthcare China joint innovation center, and a CBMG-Thermo Fisher Scientific joint innovation center.

“The recent investment from Sailing Capital Overseas Investment Ltd., of $30.6 million, will enable further clinical development by funding our current multiple clinical programs, as well as expanding our immuno-oncology pipeline with further CAR-T receptor constructs for various liquid and solid tumor indications, including, but not limited to, Anti-BCMA CAR for multiple myeloma (MM). We continue to focus on accelerating deployment of new cell therapies to the clinical stage, confident in our in-house research and development capabilities, our CMC platform, and our broad clinical development network with leading medical institutions in China.”

Click here to read the full press release.

The Conversation (0)
×